^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MRC1 expression

i
Other names: MRC1, Mannose Receptor C-Type 1, CLEC13DL, BA541I19.1, Human Mannose Receptor, Macrophage Mannose Receptor 1, CLEC13D, Macrophage Mannose Receptor 1-Like Protein 1, C-Type Lectin Domain Family 13 Member D, Mannose Receptor, C Type 1-Like 1, MMR, CD206, MRC1L1, HMR, C-Type Lectin Domain Family 13 Member D-Like, Macrophage Mannose Receptor, Mannose Receptor, C Type 1, CD206 Antigen
Entrez ID:
8d
IGF2BP3/CTCF Axis-Dependent NT5DC2 Promotes M2 Macrophage Polarization to Enhance the Malignant Progression of Lung Squamous Cell Carcinomas. (PubMed, Clin Respir J)
The IGF2BP3/CTCF axis-dependent NT5DC2 promotes M2 macrophage polarization, thereby enhancing the malignant progression of LUSC. This study was the first to reveal the role of NT5DC2 in LUSC and the underlying mechanism. The result suggests that targeting the IGF2BP3/CTCF/NT5DC2 axis may have clinical significance in the treatment of LUSC.
Journal
|
IL10 (Interleukin 10) • ITGAM (Integrin, alpha M) • TGFB1 (Transforming Growth Factor Beta 1) • MRC1 (Mannose Receptor C-Type 1) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3)
|
CD20 expression • ITGAM expression • MRC1 expression
12d
Nicotine promotes M2 macrophage polarization through α5-nAChR/SOX2/CSF-1 axis in lung adenocarcinoma. (PubMed, Cancer Immunol Immunother)
Furthermore, α5-nAChR expression was strongly linked to pSTAT3, SOX2 and M2 macrophage marker CD206 expression and negatively correlated with M1 macrophage marker CD86 expression in vivo. It is indicated that M2 macrophages are mediated by the new α5-nAChR /SOX2/CSF-1 axis in nicotine-related LUAD, which is a potential therapeutic strategy for cancer.
Journal
|
CSF1 (Colony stimulating factor 1) • SOX2 • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule)
|
CSF1 expression • MRC1 expression • SOX2 expression
23d
Oral squamous cell carcinomas drive monocytes into immunosuppressive CD25+CD163+CD206+ macrophages. (PubMed, Oral Oncol)
CD25 enhanced expression was confirmed on H143-CM moMΦ. Collectively, these data indicate that the CM from OSCC cell lines promotes the differentiation of functionally immunosuppressive macrophages resembling TAMs, and contributes to the understanding of how OSCCs create an immunosuppressive cellular environment that favors tumor growth.
Journal
|
IL2RA (Interleukin 2 receptor, alpha) • CD163 (CD163 Molecule) • ITGAX (Integrin Subunit Alpha X) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
|
CD163 expression • MRC1 expression
25d
Qingrexiaoji Recipe Regulates the Differentiation of M2 TAM via miR-29 in GC. (PubMed, Comb Chem High Throughput Screen)
In summary, these results suggested that the Qingrexiaoji recipe regulated M2 macrophage polarization by regulating miR-29a-3p/HDAC4, providing a different and innovative treatment for gastric cancer.
Journal
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • MRC1 (Mannose Receptor C-Type 1) • CD80 (CD80 Molecule) • HDAC4 (Histone Deacetylase 4) • MIR29A (MicroRNA 29a)
|
CD20 expression • IFNG expression • MRC1 expression
1m
CKAP2 Regulated by TFDP1 Promotes Metastasis and Proliferation of Colorectal Cancer through Affecting the Tumor Microenvironment. (PubMed, J Microbiol Biotechnol)
In vivo silencing of CKAP2 repressed tumor growth and metastasis. Overall, CKAP2 was positively regulated by TFDP1, which promoted tumorigenesis and metastasis in CRC.
Journal
|
IL1B (Interleukin 1, beta) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule)
|
MRC1 expression
1m
Exosomal miR-106a-5p from highly metastatic colorectal cancer cells drives liver metastasis by inducing macrophage M2 polarization in the tumor microenvironment. (PubMed, J Exp Clin Cancer Res)
CRC-derived exosomal miR-106a-5p plays a critical role in promoting liver metastasis and is a potential biomarker for the prevention and treatment of CRC liver metastasis.
Journal • Metastases
|
MIR106A (MicroRNA 106a) • MRC1 (Mannose Receptor C-Type 1)
|
MRC1 expression
2ms
NEIL3 upregulated by TFAP2A promotes M2 polarization of macrophages in liver cancer via the mediation of glutamine metabolism. (PubMed, Digestion)
This study suggested that the TFAP2A/NEIL3 axis promoted Mø M2 polarization through Gln metabolism, providing a theoretical basis for immune therapy targeting the liver cancer TME.
Journal
|
IL10 (Interleukin 10) • CCR2 (C-C Motif Chemokine Receptor 2) • MRC1 (Mannose Receptor C-Type 1) • NEIL3 (Nei Like DNA Glycosylase 3) • CD86 (CD86 Molecule) • TFAP2A (Transcription Factor AP-2 Alpha)
|
MRC1 expression
2ms
Integrins α5β1 and αvβ3 Differentially Participate in the Recruitment and Reprogramming of Tumor-associated Macrophages in the In Vitro and In Vivo Models of Breast Tumor. (PubMed, J Immunol)
In line with this, FAK inhibition during TAM polarization reduced SRC, STAT1, and STAT6 phosphorylation. In conclusion, these findings underscore the crucial role of integrins in TAM recruitment, polarization, and reprogramming in tumors.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD163 (CD163 Molecule) • MERTK (MER Proto-Oncogene, Tyrosine Kinase) • IL10 (Interleukin 10) • ITGAM (Integrin, alpha M) • TGFB1 (Transforming Growth Factor Beta 1) • STAT1 (Signal Transducer And Activator Of Transcription 1) • STAT6 (Signal transducer and activator of transcription 6) • MRC1 (Mannose Receptor C-Type 1)
|
MERTK expression • CD20 expression • MRC1 expression
2ms
CD206 accelerates hepatocellular carcinoma progression by regulating the tumour immune microenvironment and increasing M2-type polarisation of tumour-associated macrophages and inflammation factor expression. (PubMed, Discov Oncol)
The overexpression of CD206 accelerates the progression of HCC and changes the tumour immune microenvironment. The high expression of CD206 in HCC increases the M2-type polarisation of TAMs and induces the expression of both TGF-β and IL-6 in tumour tissues and serum, thereby promoting HCC progression.
Journal
|
IL6 (Interleukin 6) • TGFB1 (Transforming Growth Factor Beta 1) • MRC1 (Mannose Receptor C-Type 1)
|
CD20 expression • CD20 overexpression • CD2 overexpression • IL6 expression • MRC1 expression
2ms
Inhibition of STAT3 by 2-Methoxyestradiol suppresses M2 polarization and protumoral functions of macrophages in breast cancer. (PubMed, BMC Cancer)
Our study presents novel findings on mechanism of 2ME2 from the perspective of its effects on the polarization of the TAMs via the STAT3 signaling in breast cancer. Altogether, the data supports further clinical investigation of 2ME2 and its derivatives as therapeutic agents to modulate the tumor microenvironment and immune response in breast carcinoma.
Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • CD163 (CD163 Molecule) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • MMP9 (Matrix metallopeptidase 9) • MRC1 (Mannose Receptor C-Type 1) • CCL18 (C-C Motif Chemokine Ligand 18)
|
CD20 expression • CD163 expression • MRC1 expression
|
Panzem (2-methoxyestradiol)
6ms
Microglia-targeted inhibition of miR-17 via mannose-coated lipid nanoparticles improves pathology and behavior in a mouse model of Alzheimer's disease. (PubMed, Brain Behav Immun)
This selective targeting strategy delivers specific agents to microglia without the adverse off-target effects on other cell types. Additionally, this approach can be used to deliver other molecules to microglia and other immune cells in other organs.
Preclinical • Journal
|
MIR17 (MicroRNA 17) • MRC1 (Mannose Receptor C-Type 1)
|
MRC1 expression
6ms
TM6SF1 suppresses the progression of lung adenocarcinoma and M2 macrophage polarization by inactivating the PI3K/AKT/mtor pathway. (PubMed, Biochem Biophys Res Commun)
TM6SF1-caused inhibition of proliferation, migration, invasion and EMT, as M2 macrophage polarization was reversed by the PI3K activator in LUAD cells. TM6SF1 inactivated the PI3K/AKT/mTOR pathway to suppress LUAD malignancy and polarization of M2 macrophages, providing insight for developing new LUAD treatments.
Journal
|
CDH1 (Cadherin 1) • CD163 (CD163 Molecule) • IL10 (Interleukin 10) • MMP2 (Matrix metallopeptidase 2) • VIM (Vimentin) • CDH2 (Cadherin 2) • MMP9 (Matrix metallopeptidase 9) • MRC1 (Mannose Receptor C-Type 1) • TM6SF1 (Transmembrane 6 Superfamily Member 1)
|
CDH1 expression • MRC1 expression
7ms
PGRN is involved in macrophage M2 polarization regulation through TNFR2 in periodontitis. (PubMed, J Transl Med)
In summary, PGRN promotes macrophage M2 polarization through binding to TNFR2 in both pro- and anti-inflammatory periodontal microenvironments.
Journal
|
IL6 (Interleukin 6) • IL10 (Interleukin 10) • IL4 (Interleukin 4) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule)
|
PGR expression • MRC1 expression
7ms
Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA (clinicaltrials.gov)
P2, N=24, Recruiting, Navidea Biopharmaceuticals | Trial completion date: Sep 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Dec 2024
Trial completion date • Trial primary completion date
|
MRC1 (Mannose Receptor C-Type 1) • CRP (C-reactive protein)
|
MRC1 expression
8ms
Host-functionalization of macrin nanoparticles to enable drug loading and control tumor-associated macrophage phenotype. (PubMed, Front Immunol)
Furthermore, transcriptional profiles of macrophages indicated robust pro-inflammatory reprogramming (elevated Nos2 and Il12; suppressed Arg1 and Mrc1 expression levels) for a subset of these immuno-stimulatory agents (UNC2025 and R848)...Finally, in an intradermal MC38 tumor model, cyclodextrin-modified macrin NPs loaded with immunostimulatory drugs significantly reduced tumor growth. Therefore, efficient and effective repolarization of tumor-associated macrophages to an M1-like phenotype-via drug-loaded macrins-inhibits tumor growth and may be useful as an adjuvant to existing immune checkpoint therapies.
Journal
|
MRC1 (Mannose Receptor C-Type 1) • NOS2 (Nitric Oxide Synthase 2)
|
IL2 elevation • MRC1 expression
|
UNC2025
8ms
EGFR overexpression and macrophage infiltration correlate with poorer prognosis in HPV-negative oropharyngeal cancer via STAT6 signaling. (PubMed, Head Neck)
There is strong correlation between EGFR overexpression and M2 polarization in patients with p16-negative OPC. Immunotherapy with or without EGFR inhibitor could be considered in these high-risk patients.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • STAT6 (Signal transducer and activator of transcription 6) • MRC1 (Mannose Receptor C-Type 1)
|
EGFR overexpression • EGFR positive • CDKN2A negative • MRC1 expression
8ms
GalNAc- or Mannose-PEG-Functionalized Polyplexes Enable Effective Lectin-Mediated DNA Delivery. (PubMed, Bioconjug Chem)
The involvement of the asialoglycoprotein receptor (ASGPR) in the uptake of GalNAc-functionalized polyplexes was confirmed in the ASGPR-positive hepatocarcinoma cell lines HepG2 and Huh7. Mannose-modified polyplexes showed superior cellular uptake and transfection efficacy compared to unmodified and shielded polyplexes in mannose-receptor-expressing dendritic cell-like DC2.4 cells.
Journal
|
MUC4 (Mucin 4, Cell Surface Associated) • MRC1 (Mannose Receptor C-Type 1)
|
MRC1 expression
9ms
Detection of metastatic lymph node and sentinel lymph node mapping ​using mannose receptor targeting in in vivo mouse and rabbit uterine cancer models. (PubMed, Int J Surg)
MSA-ICG was able to distinguish metastatic LN for an extended period due to its specific tumor-associated macrophage-targeting property. Therefore, it may be a more distinguishable tracer for identifying metastatic LNs and SLNs during uterine cancer surgery. Further research is needed to confirm these results.
Preclinical • Journal • Metastases
|
MRC1 (Mannose Receptor C-Type 1)
|
MRC1 expression
9ms
Anti-metastatic effects of AGS-30 on breast cancer through the inhibition of M2-like macrophage polarization. (PubMed, Biomed Pharmacother)
In conclusion, this study shows that AGS-30 inhibits breast cancer growth and metastasis, probably through inhibiting M2-like macrophage polarization. Our findings suggest that AGS-30 may be a potential immunotherapeutic alternative for metastatic breast cancer.
Journal • IO biomarker • Metastases
|
IFNG (Interferon, gamma) • IL10 (Interleukin 10) • MMP2 (Matrix metallopeptidase 2) • CD31 (Platelet and endothelial cell adhesion molecule 1) • MMP9 (Matrix metallopeptidase 9) • STAT6 (Signal transducer and activator of transcription 6) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • MRC1 (Mannose Receptor C-Type 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
CD20 expression • CD31 expression • MRC1 expression
9ms
CD206 modulates the role of M2 macrophages in the origin of metastatic tumors. (PubMed, J Cancer)
By eliminating the expression of CD206 in M2 macrophages using siRNA, we show that the growth and metastasis of tumors was suppressed using both in vitro cell line and with experimental in vivo mouse models. In summary, we show that M2 macrophages in the blood circulation underwent a "change of loyalty" to become "cancer cells" that transformed into distal tissue metastasis, which could be suppressed by the knockdown of CD206 expression.
Journal • Metastases
|
MRC1 (Mannose Receptor C-Type 1)
|
CD20 expression • MRC1 expression
9ms
Human amniotic MSCs-mediated anti-inflammation of CD206hiIL-10hi macrophages alleviates isoproterenol-induced ventricular remodeling in mice. (PubMed, Int Immunopharmacol)
Our results demonstrated that hAMSCs effectively alleviated ISO-induced cardiac hypertrophy and fibrosis, and improved the cardiac functions in mice, and the underlying mechanisms might be related to inhibiting the inflammation and fibrosis during the ventricular remodeling through promoting the polarization of CD206hiIL-10hi macrophages in heart tissues. Our study strongly suggested that by taking the advantages of the potent immunosuppressive and anti-inflammatory effects, hAMSCs may provide an alternative therapeutic approach for prevention and treatment of VR clinically.
Preclinical • Journal
|
IL6 (Interleukin 6) • IL10 (Interleukin 10) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule)
|
CD20 expression • IL6 expression • MRC1 expression
10ms
Polymeric nanocapsules loaded with poly(I:C) and resiquimod to reprogram tumor-associated macrophages for the treatment of solid tumors. (PubMed, Front Immunol)
While no significant alterations were observed in T cell numbers (CD8, CD4 or Treg), TAM-reprogramming in treated mice was confirmed by the relative decrease of interstitial versus alveolar macrophages, having higher CD86 expression but lower CD206 and Arg1 expression in the same cells, in treated mice. Mannose-HA-protamine-NCs loaded with poly(I:C)+R848 successfully reprogram TAMs in vivo, and reduce tumor progression and metastasis spread in mouse tumors.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CD4 (CD4 Molecule) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule)
|
MRC1 expression
|
resiquimod (STM-416)
10ms
Effects of IFN-γ on the immunological microenvironment and TAM polarity in stage IA non-small cell lung cancer and its mechanisms. (PubMed, BMC Pulm Med)
In stage IA NSCLC, a low concentration of IFN-γ promotes the polarization of TAMs to the M2 phenotype in the TME model by upregulating the expression of IDO1, promoting the viability of cancer cells, inhibiting the viability of T cells and NK cells, and thus establishing an immune microenvironment conducive to tumor progression.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CD68 (CD68 Molecule) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • MRC1 (Mannose Receptor C-Type 1)
|
BCL2 expression • CD20 expression • IDO1 expression • IFNG expression • BAX expression • CD163 expression • MRC1 expression
10ms
Effect of electroacupuncture on inflammatory response and immune cells in mice with chronic inflammatory pain. (PubMed, Zhen Ci Yan Jiu)
EA may alleviate pain and swelling in mice with chronic inflammatory pain by regulating the numbers of macrophages, neutrophils, and Treg cells, as well as promoting M2 polarization of local macrophages and inhibiting the release of pro-inflammatory cytokines.
Preclinical • Journal • Immune cell
|
TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha) • ITGAM (Integrin, alpha M) • FOXP3 (Forkhead Box P3) • IL1B (Interleukin 1, beta) • MRC1 (Mannose Receptor C-Type 1) • NLRP3 (NLR Family Pyrin Domain Containing 3)
|
MRC1 expression
11ms
RSK4 promotes the macrophage recruitment and M2 polarization in esophageal squamous cell carcinoma. (PubMed, Biochim Biophys Acta Mol Basis Dis)
Collectively, these results demonstrate that RSK4 promotes the macrophage recruitment and M2 polarization by regulating the STAT3/ICAM-1 axis in ESCC, influencing tumor progression primarily in a CCL22-dependent manner. These data also offer valuable insights for developing novel agents for the treatment of ESCC.
Journal
|
ICAM1 (Intercellular adhesion molecule 1) • CCL2 (Chemokine (C-C motif) ligand 2) • CD68 (CD68 Molecule) • CCL22 (C-C Motif Chemokine Ligand 22) • MRC1 (Mannose Receptor C-Type 1) • RPS6KA6 (Ribosomal Protein S6 Kinase A6)
|
MRC1 expression
11ms
Synthesis of a Multifunctional Glyco-Block Copolymer through Reversible Addition-Fragmentation Chain Transfer Polymerization and Click Chemistry for Enzyme and Drug Loading into MDA-MB-231 Cells. (PubMed, ACS Appl Mater Interfaces)
P(PEG-co-AM)-b-PF was self-assembled into polymeric nanoparticles (BDOX-GOx@NPs) for glucose oxidase immobilization through Schiff base formation and for encapsulating the prodrug of arylboronate-linked doxorubicin (BA-DOX) under optimal conditions...MDA-MB-231 cells, which express mannose receptors, were used to establish a model in this study. The bioactivity of the nanoplatform in the two- and three-dimensional models of MDA-MB-231 cancer cells was investigated to ascertain its antitumor efficacy.
Journal
|
MRC1 (Mannose Receptor C-Type 1)
|
MRC1 expression
|
doxorubicin hydrochloride
11ms
Neutrophil peptide 1 accelerates the clearance of degenerative axons during Wallerian degeneration by activating macrophages after peripheral nerve crush injury. (PubMed, Neural Regen Res)
Neutrophil peptide 1 also downregulated inflammatory factors interleukin-1α, -6, -12, and tumor necrosis factor-α in vivo and in vitro. Thus, the results suggest that neutrophil peptide 1 activates macrophages and accelerates Wallerian degeneration, which may be one mechanism by which neutrophil peptide 1 enhances peripheral nerve regeneration.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • MRC1 (Mannose Receptor C-Type 1)
|
MRC1 expression
11ms
Medrysone promotes corneal injury repair by promoting M2-like polarization of macrophages. (PubMed, BMC Ophthalmol)
Our study suggest that Medrysone promotes corneal injury repair by inducing the M2 polarization of macrophages, providing a theoretical basis for the application of Medrysone in the treatment of corneal injury.
Journal
|
CCL2 (Chemokine (C-C motif) ligand 2) • STAT6 (Signal transducer and activator of transcription 6) • IL4 (Interleukin 4) • MRC1 (Mannose Receptor C-Type 1)
|
CD20 expression • MRC1 expression
11ms
Integrin-linked kinase expression in myeloid cells promotes colon tumorigenesis. (PubMed, Front Immunol)
In patient CRC tissue microarrays we observed elevated ILK+ myeloid (ILK+ CD11b+) cells in tumour sections compared to adjacent normal tissues, suggesting a conserved role for myeloid-ILK in CRC development in both human and animal models. This study identifies myeloid-specific ILK expression as novel driver of CRC, which could be targeted as a potential therapeutic option for advanced disease.
Journal
|
CD8 (cluster of differentiation 8) • ITGAM (Integrin, alpha M) • FOXP3 (Forkhead Box P3) • MRC1 (Mannose Receptor C-Type 1) • ILK (Integrin Linked Kinase)
|
MRC1 expression
11ms
The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation. (PubMed, Cell Mol Immunol)
Multiplex immunohistochemistry confirmed that patients with better immunotherapeutic efficacy had higher CD86, p-NF-κB p65 and NLRP3 levels, accompanied by lower CD206 expression on macrophages. Collectively, these data provide evidence that further study on APG-2575 in combination with immunotherapy for tumor treatment is required.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CD34 (CD34 molecule) • MRC1 (Mannose Receptor C-Type 1) • NLRP3 (NLR Family Pyrin Domain Containing 3) • CD86 (CD86 Molecule)
|
MRC1 expression
|
lisaftoclax (APG-2575)
12ms
Acacetin protects against sepsis-induced acute lung injury by facilitating M2 macrophage polarization via TRAF6/NF-κB/COX2 axis. (PubMed, Innate Immun)
And TRAF6 could offset the impact of acacetin. This study demonstrated that acacetin could prevent sepsis-induced ALI by facilitating M2 macrophage polarization via TRAF6/NF-κB/COX2 axis.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule) • MPO (Myeloperoxidase) • MT-CO2 (Mitochondrially Encoded Cytochrome C Oxidase II) • TRAF6 (TNF Receptor Associated Factor 6)
|
CD20 expression • PTGS2 expression • IL6 expression • MRC1 expression
12ms
Anti-inflammatory mechanisms in cancer research: Characterization of a distinct M2-like macrophage model derived from the THP-1 cell line. (PubMed, Cancer Med)
The THP-1-derived M2 macrophage based on a standardized cell line model represents a distinct anti-inflammatory TAM-like phenotype with an M2a subtype profile. This model may provide a basis for in vitro investigation of functional mechanisms in a variety of anti-inflammatory settings, particularly colon cancer development.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL1B (Interleukin 1, beta) • MRC1 (Mannose Receptor C-Type 1)
|
CD20 expression • CXCL8 expression • MRC1 expression
12ms
Clinical Outcomes of Small Cell Carcinoma of the Genitourinary Tract and the Prognostic Significance of the Tumor Immune Microenvironment. (PubMed, Cancer Res Treat)
All patients with ED (n=31, 40.3%) received etoposide plus platinum (EP) as initial treatment and median overall survival (OS) was 9.7 months (95% CI 7.1-18.6 months)...The tumor immune phenotypes were significantly associated with survival. This finding provides new insights for treating GU SCC.
Clinical data • Journal
|
PD-L1 (Programmed death ligand 1) • CD68 (CD68 Molecule) • MRC1 (Mannose Receptor C-Type 1)
|
PD-L1 expression • CD20 expression • MRC1 expression
|
etoposide IV
12ms
Prognostic and clinicopathological significance of MRC2 expression in head and neck squamous cell carcinoma. (PubMed, J Stomatol Oral Maxillofac Surg)
Our results suggest that MRC2 could be used as a novel prognostic marker and therapeutic target for HNSCC.
Journal
|
MRC2 (Mannose Receptor C Type 2)
|
MRC1 expression
12ms
Glioma-derived S100A9 polarizes M2 microglia to inhibit CD8+T lymphocytes for immunosuppression via αvβ3 integrin/AKT1/TGFβ1. (PubMed, Biochim Biophys Acta Mol Cell Res)
In human glioma samples, S100A9 expression was positively associated with CD206 expression, but negatively correlated with CD8+T lymphocyte accumulation in the TME. Our data indicated that glioma-derived S100A9 has a promising ability to manipulate non-malignant cells and promote immune evasion in the TME, providing valuable insight into the mechanism by which S100A9 participates in the progression of glioma.
Journal
|
CD8 (cluster of differentiation 8) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • IFNG (Interferon, gamma) • IL2 (Interleukin 2) • S100A9 (S100 Calcium Binding Protein A9) • TGFB1 (Transforming Growth Factor Beta 1) • MRC1 (Mannose Receptor C-Type 1)
|
CD20 positive • MRC1 expression • S100A9 expression
12ms
Inhibition of inflammation and infiltration of M2 macrophages in NSCLC through the ATF3/CSF1 axis: Role of miR-27a-3p. (PubMed, Int J Exp Pathol)
Overall, the study suggested that miR-27a-3p might inhibit the ATF3/CFS1 axis, regulate the M2 polarization of macrophages and ultimately hinder the progress of NSCLC. This research might provide a new therapeutic strategy for NSCLC.
Journal
|
CD163 (CD163 Molecule) • CSF1 (Colony stimulating factor 1) • IL10 (Interleukin 10) • TCF3 (Transcription Factor 3) • CD68 (CD68 Molecule) • TGFB1 (Transforming Growth Factor Beta 1) • MIR27A (MicroRNA 27a) • MRC1 (Mannose Receptor C-Type 1) • ATF3 (Activating Transcription Factor 3)
|
MRC1 expression
1year
RGDK-lipopeptide for targeting genetic vaccines to antigen presenting cells. (PubMed, Biomed Mater)
Findings in the fluorescence resonance energy transfer based membrane fusogencity assay revealed that the enhanced macrophage transfection efficiency of the liposomes containing RGDK-lipopeptide, endosome-disrupting histidinylated and DOPE may originate from its higher membrane fusogenicity than that for liposomes containing only RGDK-lipopeptide and DOPE. The presently described biologically safe liposomal formulations of RGDK-lipopeptide are expected to find biomedical applications in future for combating cancer and infectious diseases through genetic immunizations.
Journal
|
MRC1 (Mannose Receptor C-Type 1)
|
MRC1 expression
1year
Albumin-based Drug Delivery System Targeting Mannose Receptors and Its Application to Medical Treatments (PubMed, Yakugaku Zasshi)
A complex of monoPEG-Man-HSA with paclitaxel suppressed tumor growth by decreasing the number of TAM/CAF and the stroma area. For the present study, we focused on the mannose receptors expressed in macrophages and fibroblasts, and developed drug delivery carriers that target these cells. Considering the excellent drug-carrying capacity and high biocompatibility of HSA, it is expected that this research will pave the way for innovative pharmacotherapy to treat unmet medical needs, i.e., intractable liver diseases and cancer.
Journal
|
IFNA1 (Interferon Alpha 1) • MRC1 (Mannose Receptor C-Type 1)
|
MRC1 expression
|
paclitaxel
1year
A Study of Adipose Tissue in Adaptive Responses to Exercise (clinicaltrials.gov)
P=N/A, N=60, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
Enrollment open
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CD163 (CD163 Molecule) • CCL2 (Chemokine (C-C motif) ligand 2) • CD68 (CD68 Molecule) • MRC1 (Mannose Receptor C-Type 1) • LEP (Leptin)
|
CD163 expression • IL6 expression • MRC1 expression
1year
Calcitriol suppresses gastric cancer progression and cisplatin resistance by inhibiting glycolysis and M2 macrophage polarization through inhibition of mTOR activation. (PubMed, Environ Toxicol)
Additionally, calcitriol hindered CCM-induced M2 macrophage polarization by reducing CD206 expression and increasing TNFα gene expression in THP1-derived macrophages, attenuating cisplatin resistance. These findings suggest that calcitriol may impede gastric cancer progression by targeting glycolysis and M2 macrophage polarization through the regulation of mTOR activation in the TME.
Journal
|
LDHA (Lactate dehydrogenase A) • CCND1 (Cyclin D1) • TNFA (Tumor Necrosis Factor-Alpha) • GLI2 (GLI Family Zinc Finger 2) • MRC1 (Mannose Receptor C-Type 1) • SLC2A1 (Solute Carrier Family 2 Member 1)
|
CCND1 expression • MRC1 expression
|
cisplatin
1year
M2 tumor-associated macrophage promoted DNA methylation in lung cancer metastasis via intensifying EZH2. (PubMed, Anticancer Drugs)
Of note, GSK126 and si-EZH2 offset the M2 type TAM's effects, and inhibited the LLC-1 cell metastasis, DNA methylation and tumor growth. M2 type TAM promoted DNA methylation in LLC-1 cells and LLC-1 cell-bearing mice, which is related to the intensified EZH2.
Journal • Epigenetic controller
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • MRC1 (Mannose Receptor C-Type 1)
|
CD20 expression • MRC1 expression
|
GSK2816126
1year
Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model. (PubMed, J Cancer Res Clin Oncol)
In conclusion, these results suggest that PD-L1, CD86, and CD206 may be involved not only in the occurrence and development of HCC, but also in immune regulation, indicating the potential role of PD-L1 and CD86 as potential biomarkers and new therapeutic targets for prognosis assessment of liver cancer.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule)
|
PD-L1 overexpression • CD20 positive • MRC1 expression